Interleukin 6 and Rheumatoid Arthritis
Tóm tắt
Interleukin-6 (IL-6) is a representative cytokine featuring pleiotropic activity and redundancy. A transient synthesis of IL-6 contributes to host defense against infectious agents and tissue injuries by inducing acute phase reactions and immunological and hematopoietic responses. However, uncontrolled persistent production of IL-6 may lead to the development of several immune-mediated diseases. Rheumatoid arthritis (RA) is a chronic disease with joint and systemic inflammation resulting from immunological abnormalities and it has been found that IL-6 plays a key role in the development of this disease. Clinical trials in various parts of the world of tocilizumab, a humanized anti-IL-6 receptor antibody, have proved its efficacy and tolerable safety either as monotherapy or in combination with disease-modifying antirheumatic drugs. As a result, it is currently used as a first-line biologic for the treatment of moderate-to-severe RA in more than 100 countries. Clarification of the mechanism(s) through which tocilizumab exerts its effect on RA and of the reason(s) why IL-6 is continuously produced in RA can be expected to lead to the best use of this agent for RA patients and aid in investigations into the pathogenesis of RA.
Từ khóa
Tài liệu tham khảo
2013, Rheumatology: Current Research, 3
1992, Proceedings of the National Academy of Sciences of the United States of America, 89, 232, 10.1073/pnas.89.1.232
1987, Proceedings of the National Academy of Sciences of the United States of America, 84, 7251, 10.1073/pnas.84.20.7251
1990, Immunology Today, 11, 443
1989, Proceedings of the National Academy of Sciences of the United States of America, 86, 7547, 10.1073/pnas.86.19.7547
1992, The Journal of Rheumatology, 19, 22
1993, Cancer Research, 53, 851
2003, The Journal of Rheumatology, 30, 1426
2011, Cochrane Database of Systematic Reviews, 2
2012, Annals of the Rheumatic Diseases, 71, 188
2011, Clinical and Experimental Rheumatology, 29, 921